FDA Drug Safety Office Is “Separate, But Unequal,” Senate Committee Says

A Senate committee investigation into FDA's handling of pediatric suicidality concerns with antidepressant drugs is focusing on the "unequal" status of the Office of Drug Safety and the Office of New Drugs